Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second AR-Directed Therapy in Metastatic Castration-resistant Prostate Cancer
jRCT2011240073Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of xaluritamig in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Amgen. Primary endpoint: Overall Survival (OS). Started Dec 2024; status: active, not recruiting.
02
Drugs
xaluritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2011240073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240073.